Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CLYM

Climb Bio Inc

Dec 12 • 11:22AM ET

2.88

Dollar change -0.22
Percentage change -7.10	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX CRSP BMRN ALNY IONS RARE EXEL NBIX RNA EDIT

| Held by: VTI IWM VXF IWN VTWO IWC VTWV RSSL IWO AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.13	Insider Own	23.36%	Shs Outstand	67.22M	Perf Week	-1.03%
Market Cap	193.60M	Forward P/E	-	EPS next Y	-1.57	Insider Trans	393.97%	Shs Float	51.52M	Perf Month	-24.21%
Income	-69.12M	PEG	-	EPS next Q	-0.15	Inst Own	71.05%	Short Float	9.50%	Perf Quarter	-65.96%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	21.71%	Short Ratio	9.39	Perf Half Y	-66.86%
Book/sh	3.25	P/B	0.88	EPS next Y	-	ROA	-41.27%	Short Interest	4.90M	Perf Year	14.74%
Cash/sh	2.88	P/C	1.00	EPS next 5Y	-	ROE	-42.08%	52W Range	2.43 - 11.55	Perf YTD	6.67%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-46.72%	ROI	-31.59%	52W High	-75.06%	Beta	-0.40
Dividend TTM	-	Quick Ratio	57.73	Sales past 5Y	0.00%	Gross Margin	-	52W Low	18.52%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	57.73	EPS Y/Y TTM	-44.51%	Oper. Margin	-	RSI (14)	35.00	Volatility	5.09% 7.29%
Employees	9	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	9.48%	Payout	-	Rel Volume	0.22	Prev Close	3.10
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	521.44K	Price	2.88
SMA20	-6.92%	SMA50	-26.59%	SMA200	-49.31%	Trades		Volume	36,196	Change	-7.10%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-24	Initiated	Leerink Partners	Outperform	$10

Nov-12-24 04:05PM	Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -6.40% -7.11%
Nov-11-24 07:00AM	Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board (GlobeNewswire) +7.12%
Oct-31-24 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event (GlobeNewswire) -6.25%
Oct-11-24 12:30PM	Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire) +5.45%
07:00AM	Loading…
Oct-04-24 07:00AM	Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 (GlobeNewswire)
Oct-03-24 10:00AM	Climb Bio to Host Virtual Investor Event on October 15, 2024 (GlobeNewswire)
Oct-02-24 07:04PM	Eliem Therapeutics Changes Name to Climb Bio (Exec Edge)
09:00AM	Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. (GlobeNewswire)
Sep-11-24 07:00AM	Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit (GlobeNewswire)
Aug-26-24 07:00AM	Eliem Therapeutics Announces Additions to its Leadership Team (GlobeNewswire)
Aug-14-24 06:05AM	Eliem Therapeutics Reports Second Quarter Financial Results (GlobeNewswire)
Jul-24-24 12:11AM	Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells Shares (GuruFocus.com)
Jul-19-24 03:00PM	Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ... (GuruFocus.com) +7.83%
Jul-18-24 01:01AM	EVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM) (GuruFocus.com)
12:42AM	Loading…
Jul-17-24 12:42AM	Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ... (GuruFocus.com)
Jul-12-24 01:46AM	Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells 105,931 Shares (GuruFocus.com)
Jun-28-24 07:00AM	Eliem Therapeutics Announces its Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) -5.58%
Jun-27-24 04:01PM	Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement (GlobeNewswire)
May-15-24 01:53PM	ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-11-24 02:42PM	Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal (Benzinga) +71.54%
07:00AM	Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement (GlobeNewswire)
Apr-05-24 06:53AM	ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023 (InvestorPlace) -6.81%
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) -8.39%
Jul-20-23 06:45AM	Eliem Therapeutics Announces Plans to Explore Strategic Alternatives (GlobeNewswire) +6.43%
May-11-23 04:10PM	Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights (GlobeNewswire) -10.22%
Apr-21-23 12:00PM	We're Hopeful That Eliem Therapeutics (NASDAQ:ELYM) Will Use Its Cash Wisely (Simply Wall St.)
10:39AM	Top 10 Stocks Activist Investors Are Targeting (Insider Monkey)
Mar-06-23 04:10PM	Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights (GlobeNewswire)
Feb-23-23 12:38AM	Eliem Therapeutics slashing staff amid leadership shakeup (American City Business Journals) +24.35%
09:31AM	Loading…
Feb-10-23 09:31AM	Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce (Benzinga)
Feb-09-23 04:01PM	Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition (GlobeNewswire)
Nov-30-22 07:00AM	Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference (GlobeNewswire) -5.19%
Nov-14-22 06:10AM	Eliem Therapeutics Reports Third Quarter Financial and Business Highlights (GlobeNewswire)
Nov-12-22 08:47AM	Is Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-08-22 07:00AM	Eliem Therapeutics to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-22 11:20AM	Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study (Benzinga)
07:00AM	Eliem Therapeutics Provides Update on Pipeline Progress (GlobeNewswire)
Aug-15-22 06:10AM	Eliem Therapeutics Reports Second Quarter Financial and Business Highlights (GlobeNewswire)
Aug-02-22 09:33AM	Eliem's stock slides 20% after saying it will discontinue development of pain treatment (MarketWatch) -10.53%
07:58AM	Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setback (Benzinga)
07:00AM	Eliem Therapeutics Provides ETX-810 Program Update (GlobeNewswire)
Jul-18-22 09:20AM	Eliem Announces Updated Development Plans For Its Delayed Depression Candidate (Benzinga)
07:00AM	Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder (GlobeNewswire)
Jul-07-22 07:00AM	Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022 (GlobeNewswire) +5.92%
Jun-27-22 04:01PM	Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP) (GlobeNewswire) +6.30% -6.19%
May-16-22 06:10AM	Eliem Therapeutics Reports First Quarter Financial and Business Highlights (GlobeNewswire) -23.41%
May-10-22 10:45AM	Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4 (Zacks)
May-09-22 09:55AM	Eliem Therapeutics, Inc. (ELYM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-25-22 07:00AM	Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs (GlobeNewswire) -55.76%
Apr-05-22 07:00AM	Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs (GlobeNewswire)
Mar-21-22 07:00AM	Eliem Therapeutics to Present at Stifels 2022 CNS Days (GlobeNewswire)
Mar-07-22 04:10PM	Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights (GlobeNewswire)
Feb-11-22 07:00AM	Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -11.17%
Feb-07-22 07:00AM	Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022 (GlobeNewswire)
Jan-18-22 07:00AM	Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones (GlobeNewswire)
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-08-21 04:01PM	Eliem Therapeutics Reports Third Quarter Financial and Business Highlights (GlobeNewswire) -10.19% +6.33%
Nov-04-21 07:00AM	Eliem Therapeutics to Participate at Four Upcoming Investor Conferences (GlobeNewswire)
Oct-04-21 10:54AM	Buy These 3 New Stocks Before They Jump Over 60%, Say Analysts (TipRanks)
Sep-13-21 04:10PM	Eliem Therapeutics Reports Second Quarter Financial Results (GlobeNewswire) -12.27%
Aug-16-21 10:22AM	Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August (Benzinga) +8.44%
Aug-12-21 09:06PM	Eliem Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters Option to Purchase Additional Shares (GlobeNewswire) -15.95% -16.67%
Aug-09-21 10:33PM	Eliem Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Pimblett Emily	CHIEF ACCOUNTING OFFICER	Sep 20 '24	Sale	8.18	1,191	9,741	7,564	Sep 20 09:53 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 22 '24	Sale	8.03	69,005	554,170	31,317	Jul 23 05:04 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 19 '24	Sale	7.21	60,201	434,325	100,322	Jul 23 05:04 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 18 '24	Sale	6.93	38,576	267,332	160,523	Jul 19 11:12 AM
Morisset Valerie	EVP, R&D AND CSO	Jul 17 '24	Sale	6.91	3,207	22,160	199,099	Jul 19 11:12 AM
Morisset Valerie	EVP, R&D AND CSO	Jul 16 '24	Sale	7.13	50,000	356,500	202,306	Jul 17 06:11 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 12 '24	Sale	7.07	50,000	353,500	294,683	Jul 16 06:14 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 15 '24	Sale	7.01	42,377	297,063	252,306	Jul 16 06:14 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 11 '24	Sale	7.11	50,000	355,500	344,683	Jul 11 08:45 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 10 '24	Sale	6.83	50,000	341,500	394,683	Jul 11 08:45 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 09 '24	Sale	6.66	5,931	39,500	444,683	Jul 11 08:45 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 05 '24	Sale	7.06	12,342	87,135	450,614	Jul 09 04:46 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 01 '24	Option Exercise	0.00	7,649	2	512,956	Jul 03 02:42 PM
Morisset Valerie	EVP, R&D AND CSO	Jul 03 '24	Sale	6.76	50,000	338,000	462,956	Jul 03 02:42 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jun 27 '24	Buy	3.84	13,008,546	49,952,817	23,521,757	Jul 01 09:29 PM
Pimblett Emily	CHIEF ACCOUNTING OFFICER	Jun 20 '24	Sale	7.21	1,245	8,982	3,755	Jun 21 02:57 PM
Morisset Valerie	EVP, R&D AND CSO	Apr 05 '24	Option Exercise	0.00	17,847	4	505,307	Apr 08 05:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLYM

Climb Bio Inc

Upgrade your FINVIZ experience